Chimerix
anti preclinical activity that is a viral inhibitor replicating | Chimerix
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
34 of 38
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
August 2023
anti preclinical activity that is a viral inhibitor efficacy in mouse adapted model viral lung titer across multiple million grant to fund formulations that could enable oral administration with improved lung delivery inhaled liquid aerosol formulation minimal systemic exposure replicating hours post infection | Chimerix
Investor Presentation
May 2023
anti preclinical activity that is a viral inhibitor replicating | Chimerix
Related slides by other companies
Genelux
Investor Presentation
December 2023
program builds on completed trials to exploit competitive advantages estimated billion dollar plus annual commercial opportunity us | Genelux
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights